Clinical Trial Update: Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a triple therapy consisting of lisocabtagene maraleucel, nivolumab, and ibrutinib for Richter transformation (transformed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Richter Syndrome

Drugs mentioned

• Ibrutinib (ibrutinib)
• Lisocabtagene maraleucel (lisocabtagene maraleucel)
• nivolumab (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Status: RECRUITING